Drug Database
IN

interferon alfa-2b (Inferon)

✓ Approved

Virchow Biotech · IFNAR2 · 重组蛋白

什么是 interferon alfa-2b?

interferon alfa-2b 是一种重组蛋白,由Virchow Biotech研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Inferon
公司Virchow Biotech
药物类别重组蛋白
分子靶点IFNAR2
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

interferon alfa-2b 作用于 1 个分子靶点:

IFNAR2interferon alpha and beta receptor subunit 2 (IFNARB, IFN-alpha-REC)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

interferon alfa-2b 针对 3 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Chronic myeloid leukaemia✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsHepatitis C✓ Approved

相关研究文献

PubMedDrugs2026-11-17

Insulin Efsitora Alfa: First Approval.

Blair Hannah A HA

Insulin efsitora alfa (Onswik™) is a once-weekly ultra-long-acting recombinant basal insulin being developed by Eli Lilly and Company for the treatment of diabetes mellitus. Administered once weekly as a subcutaneous injection, insulin efsitora alfa is designed to provide a simplified treatment regimen relative to standard daily basal insulins. On 20 August 2026, insulin efsitora alfa received its first approval in the EU for the treatment of type 2 diabetes mellitus (T2DM) in adults. On 24 September 2026, insulin efsitora alfa was approved in the USA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Insulin efsitora alfa is approved in the EU, Iceland, Norway, Liechtenstein and the USA and is under regulatory review in the UK and Japan for T2DM. This article summarizes the milestones in the development of insulin efsitora alfa leading to this first approval for T2DM.

PMID 43040187
阅读全文 →
PubMedFrontiers in immunology2026-11-17

HERC5-mediated co-translational ISGylation in innate immunity: molecular mechanisms, context-dependent regulation, and therapeutic potential.

Huang Xiaomei X, Huang Fengdie F, Luo Dongrong D, Li Shiying S et al.

HERC5 is the predominant E3 ligase for interferon-stimulated gene 15 (ISG15) in human cells and is now considered a central component of interferon-driven innate immune regulation. Unlike conventional E3 ligases that primarily modify mature proteins, HERC5 has been reported to mediate co-translational ISGylation by associating with ribosomes and modifying nascent polypeptides during protein synthesis, providing a mechanistic link between interferon activation, protein modification, and rapid cellular adaptation during immune responses. Accumulating evidence suggests that HERC5-mediated ISGylation contributes to multiple aspects of antiviral defense, amplification of interferon signaling, pathogen-host interactions, and immune homeostasis. Beyond its canonical antiviral functions, emerging studies reveal that dysregulated HERC5 activity contributes to immune-associated pathological processes, including inflammatory disorders, tumor-associated immune regulation, and stress-induced cellular adaptation. However, the molecular principles that determine how HERC5 generates distinct biological outcomes across cellular and pathological contexts remain incompletely understood. In this Review, we critically synthesize selected mechanistic, experimental, and clinical evidence on HERC5-mediated co-translational ISGylation and propose a context-dependent regulatory framework in which HERC5 functions as an interferon-responsive ISGylation hub. We discuss three interconnected regulatory axes: the interferon-ISGylation axis, which governs antiviral immunity and innate immune signaling amplification; the stress adaptation and homeostasis axis, which links HERC5 activity to cellular adaptation and proteome regulation during immune responses; and the disease-associated rewiring axis, which describes how altered HERC5-mediated ISGylation contributes to pathological immune signaling. These axes provide a conceptual framework for comparing experimentally established mechanisms with disease-associated observations rather than implying a universal causal pathway. Furthermore, we highlight the emerging translational potential of HERC5 as a biomarker and therapeutic target, including nanobody-based ISGylation-targeting chimeras (NITACs) as a programmable strategy for modulating ISGylation-dependent immune pathways. Collectively, this Review highlights HERC5-mediated co-translational ISGylation as an emerging regulatory interface linking innate immunity, proteostasis, and immune-associated diseases.

PMID 43041922
阅读全文 →
PubMedFrontiers in immunology2026-11-17

BAP1 as a novel regulator of type I interferon signaling through transcriptional control of key response machinery components.

Mortazavi Yasaman Y, Zhang Hanyue H, Herrera Robert R, Cook Ryan R et al.

Type I interferon (IFN-I) signaling is critical for dual immunity, defending against microbial infections and augmenting anti-tumor immune responses. Research in the past few decades have identified the key machinery components and over 300 interferon-stimulated genes (ISGs) that comprise the IFN-I signaling network. While cascade amplification mechanisms ensure robust pathway activation, appropriate expression of signaling components is essential for maintaining pathway sensitivity, enabling efficient signal amplification, and providing adequate host responses. Here, we identified BRCA1-associated protein-1 (BAP1) as a positive regulator of the IFN-I signaling pathway through a genome-wide CRISPR/Cas9 screen in murine macrophage Raw264.7 cells stimulated with cGAMP. We confirmed both the enzymatic activity and nuclear localization of BAP1 were essential for this regulation. Our findings reveal that BAP1 regulates a broad transcriptional program essential for IFN-I responses, including IFNAR1 and IFNAR2. BAP1 deficient cells failed to mount an effective IFN-I response, showing markedly reduced ISGs and resulting in uncontrolled viral replication. These findings together highlight an essential role of BAP1 in controlling IFN-I signaling and antiviral responses.

PMID 43041536
阅读全文 →
PubMedJournal of virology2026-11-17

A chicken interferon-stimulated gene screen reveals limited genes restricting influenza virus replication.

Barkhymer Alison J AJ, Becker Jordan T JT, Shepherd Frances K FK, Mickelson Clayton K CK et al.

Avian influenza A virus (IAV) is a major global health threat. Not only does it cause significant economic losses to the agricultural industry, but it also presents a risk of spillover into the human population. However, several obstacles must be overcome for a successful cross-species transmission event to occur. One of these obstacles is the innate immunity of the host. While the innate immune response to IAV in humans has been well-studied, the innate immune response to IAV in birds is not as well understood. Here, we explore the interferon-induced immune response by identifying interferon-stimulated genes (ISGs) in chicken, quail, and duck cells, and find that they are largely species-specific. Using this data, we performed a CRISPR knockout ISG screen against two strains of IAV, the mouse-adapted PR8, and the low pathogenicity avian IAV isolate WF10. We find that for PR8, IFITM3 is the dominant restrictor of viral replication with several additional hits with modest effects, consistent with previous work in mammals. For avian WF10, IFITM3 was also a hit; however, there were two additional hits absent for PR8, the HSP70 co-chaperone protein BAG5 and the deubiquitinase OTUD4. Overall, these findings confirm the divergence of interferon-mediated immunity between species and establish a screening system that can be used to identify ISGs important for viral restriction in avian species.IMPORTANCEWild birds, especially waterfowl and shorebirds, are the primary natural reservoir for influenza A viruses. These birds can transmit IAV to domestic poultry, where the spillover risk to humans increases. Chickens are the most common species of domestic poultry worldwide and frequently infected with avian influenza viruses. Despite this, relatively little is known about how their immune system responds to influenza infection. This lack of knowledge creates a barrier to finding ways of preventing or mitigating IAV infection in chicken flocks. In this study, we characterized the interferon-induced immune response to IAV in chickens and found that only a small subset of ISGs were responsible for restricting IAV in chicken cells.

PMID 43042969
阅读全文 →
PubMedMolecular & cellular oncology2026-11-17

Expression and activity of prolactin receptor isoforms in non-malignant and malignant lung cells.

Rico-Luna Anaiza A, González-Sánchez Ignacio I, Almeida-Aguirre Ericka Karol Pamela EKP, Vergara Edgar E et al.

In recent years, the involvement of prolactin (PRL) in different malignancies, such as breast and prostate cancer, has been reported. Recently, prolactin was also proposed as a biomarker for lung cancer, but its molecular mechanisms remain to be explored in this tissue. The aim of this work was to assess the expression of the prolactin receptor (PRLR) and its isoforms, using non-tumorigenic bronchial epithelial (BEAS-2B) cells as a non-malignant model, and A549 and SK-LU-1 cell lines derived from lung adenocarcinoma (LUAD) as a malignant model. Moreover, the STAT5 signaling pathway was analyzed after the administration of PRL, along with its effects on cell viability in these lung cancer cell lines. PRLR expression was assessed by Western blot, RT-PCR, and immunofluorescence, while STAT5 activation was evaluated via Western blot for p-STAT5 detection and immunofluorescence for nuclear translocation. Additionally, cell viability was determined using the MTT assay. We found differential expression of PRLR isoforms at both the mRNA and protein levels. PRLR protein expression was differentially localized in the subcellular compartments of the A549 and SK-LU-1 LUAD cell lines. Furthermore, even at low doses of PRL treatment, an increase in p-STAT5 (a marker of PRLR canonical pathway) and its subsequent translocation to the nucleus were observed in the SK-LU-1 cell line, indicating the activation of this pathway by PRL. Furthermore, we did not observe significant differences in cell viability after PRL administration at low doses; however, treatment with higher doses of PRL increased the cell viability in SK-LU-1 cells at 24 h and in BEAS-2B cells at 72 h. Overall, the results indicate that isoforms of PRLR are expressed in non-tumorigenic and LUAD cells, and that PRL treatment induces STAT5 translocation, suggesting that its effects may be mediated by different PRLR isoforms. However, further studies involving other types of lung cell lines are needed to determine their role in lung pathophysiology.

PMID 43042257
阅读全文 →
PubMedJSES international2026-11-17

Mechanical investigation of the distal acromial tip fusion for reverse shoulder arthroplasty.

Simcox Trevor G TG, DelliCarpini Gennaro G, Chen Cong C, Dzieza Wojciech K WK et al.

Acromial stress fractures are a potentially catastrophic complication of reverse total shoulder arthroplasty (rTSA). Our ability to delineate at risk patients is improving, but treatments that modify risk are limited. The distal acromial tip fusion (DATF) is a procedure performed concomitantly with rTSA, wherein humeral head autograft is used to create an osseous fusion between the undersurface of the anterior acromion and the superior glenoid rim. This may reinforce the anterior acromion process and increase the rigidity of the shoulder suspensory complex. A mechanical study was conducted using osteoporotic sawbones (fourth generation, Sawbones USA). An MTS universal testing machine was used to apply an inferiorly directed axial load to the anterior acromion. Six DATF procedures were performed utilizing grafts fashioned from cancellous foam blocks (Sawbones USA). Six DATF and 6 control scapulae were then affixed to an epoxy testing block and subjected to a load-to-failure assessment. Force was measured in Newtons (N), and displacement distance in millimeters (mm). Key parameters such as stiffness (N/mm), maximum load (N), displacement at maximum load (mm), mode of failure, and fracture pattern were recorded for each model. Statistical comparisons of continuous variables were conducted using two-sided Welch t-tests. DATF group demonstrated a 64% increase in stiffness (59.7 ± 14.6 vs. 36.5 ± 3.2 N/mm, P = .011) and a 111% increase in maximum load to failure (436.9 ± 62.3 vs. 206.9 ± 42.7 N, P < .001) compared to controls. No significant differences in acromion displacement at max load were observed between groups (7.9 ± 3.0 vs. 7.9 ± 2.4 mm, P = .986). Control scapulae exhibited 2 Levy type 2b and 4 Levy type 3 fractures. The DATF group displayed 5 Levy type 2b fractures and 1 Levy type 1 pattern. In the DATF group, construct failure occurred predominantly via screw bending at the graft-coracoid interface (4 models), with a secondary mode involving vertical graft split (2 models). Performance of a DATF at the time of rTSA imparts significantly increased stiffness and maximum load to failure of the acromion from an inferiorly directed axial load when compared to controls. Clinical studies are warranted to demonstrate osseous union and whether this procedure mitigates acromial fracture risk in-vivo.

PMID 43041217
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多interferon alfa-2b